SHIVALIKBSEShivalik Rasayan LtdHighNeutral
Announced Wed, 27 May · 16:45 IST

We wish to inform you that the Board of Directors of the Company approved the Audited Financial results (Standalone & Consolidated) for the quarter and year ended on 31.03.2026

Pat NegativeResults View source PDF

SHIVALIK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.6%1-day move
₹261.00
prior close
₹274.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.3+2.0+3.8+4.6+4.6-3.5-6.1-8.0-8.9-9.3-16.5-14.4
Up moveDown movePending
AI summary

Shivalik Rasayan Ltd reported audited standalone revenue of Rs 17,023.35 lakh for FY26, up 14.1% from Rs 14,922.59 lakh in FY25. However, standalone net profit dropped sharply to Rs 817.25 lakh from Rs 1,386.68 lakh in FY25, a decline of about 41%. On consolidated basis, revenue grew 18% to Rs 36,800.32 lakh while net profit fell 12% to Rs 1,796.88 lakh. The board recommended a dividend of Rs 0.50 per share (10%). The auditors issued unmodified opinions on both standalone and consolidated results. The company also announced a change in internal auditor (from Amar Sharma & Co to Arun Agarwal & Co) and the resignation of Mr Sanjay Bansal as Non-Executive Director.

Likely market impact

The significant 41% decline in standalone PAT despite 14% revenue growth signals margin compression and is a concern for shareholders. The consolidated results including associate Medicamen Biotech Ltd show similar profit decline trends.